RESOLVE
A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol
| Coordinatore | ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 13˙675˙103 € |
| EC contributo | 10˙548˙374 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-01-01 - 2017-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | coordinator | 2˙489˙901.00 |
| 2 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 1˙221˙793.00 |
| 3 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 962˙241.00 |
| 4 |
TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
NL (EINDHOVEN) | participant | 943˙898.00 |
| 5 |
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
Organization address
address: N PLASTIRA STR 100 contact info |
EL (HERAKLION) | participant | 808˙498.00 |
| 6 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 792˙600.00 |
| 7 |
INSTITUT PASTEUR DE LILLE FONDATION
Organization address
address: 1 Rue du professeur Calmette contact info |
FR (LILLE) | participant | 771˙602.00 |
| 8 |
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Organization address
address: WILRIJKSTRAAT 10 contact info |
BE (EDEGEM) | participant | 591˙050.00 |
| 9 |
GENEXPLAIN GMBH
Organization address
address: AM EXER 10 B contact info |
DE (WOLFENBUTTEL) | participant | 584˙599.00 |
| 10 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 403˙758.00 |
| 11 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 400˙000.00 |
| 12 |
Centrum fur Angewandte Nanotechnologie (CAN) GmbH
Organization address
address: Grindelallee 117 contact info |
DE (Hamburg) | participant | 373˙600.00 |
| 13 |
ACIES Consulting Group SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 204˙834.00 |
| 14 |
NOVAMEN SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CVD; type 2 diabetes, T2DM; non-alcoholic fatty liver disease, NAFLD). RESOLVE will deliver on 6 specific objectives: i) build a computational model for analyzing the kinetics of plasma lipids, lipoproteins and their interactions with glucose metabolism. ii) apply the iterative systems biology cycle for calibrating, validating and improving the computational model in dedicated studies in mice iii) build, calibrate and validate the computational model for use in humans. iv) analyze – based on model and experimental data – which processes in the murine metabolic network regulate the physiological response to perturbations in lipid, lipoprotein and glucose metabolism and how these interact. v) analyze – based on model and experimental data – which processes in the human metabolic network regulate the physiological response to perturbations in lipid, lipoprotein and glucose metabolism and how these interact vi) use the human model to identify network-based drug targets aimed at restoring the metabolic dyslipidemia and glycemic control in patients with MetS and associated comorbidities. RESOLVE 60-months project will result into a novel strategy for development of therapeutic strategies for MetS patients with T2DM, NAFLD or CVD.'